<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02521948</url>
  </required_header>
  <id_info>
    <org_study_id>PSD-051</org_study_id>
    <nct_id>NCT02521948</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate the Safety and Performance of MANTA Vascular Closure Device</brief_title>
  <official_title>Clinical Study to Evaluate the Safety and Performance of MANTA Vascular Closure Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Essential Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Essential Medical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and performance of the MANTA Vascular
      Closure Device (VCD) to close the arteriotomy following percutaneous cardiovascular
      procedures utilizing large bore sheaths for purposes of supporting a CE Mark (Conformite
      Europeenne--&quot;European Conformity&quot;) and other regulatory submissions. The study will assess
      whether the MANTA VCD is safe and performs as intended for large-bore vascular closure after
      interventional procedures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the safety and performance of MANTA in achieving
      hemostasis in femoral arterial access sites in patients undergoing percutaneous transcatheter
      interventional procedures using a 10-18F procedure sheath (such as Transcather Aortic Valve
      Replacement (TAVR), Balloon Aortic Valvuloplasty (BAV) and Endovascular Aneurysm Repair
      (EVAR)) for purposes of obtaining a CE Mark in the European Union.

      The study will evaluate hemostasis success, time to hemostasis and ambulation, treatment
      success, and the rate of access-site-related complications in comparison to published
      literature on other hemostasis techniques for closing these large bore punctures (primarily,
      surgical closure and suture-mediated percutaneous closure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Major Complications</measure>
    <time_frame>Within either the first 30 days (plus or minus 7 days) after the procedure or the first 60 days (plus or minus 14 days) after the procedure</time_frame>
    <description>Composite endpoint that includes any of the following adverse events:
Access site-related bleeding requiring blood transfusion or vascular repair
Vascular injury requiring repair (e.g. perforation, dissection, arterio-venous fistula, retroperitoneal bleed, pseudoaneurysm)
Femoral artery stenosis at the access site requiring intervention
New ipsilateral lower extremity ischemia causing a threat to the viability of the limb
Access site-related infection requiring intravenous antibiotics and/or extended hospitalization
New onset access site-related neuropathy in the ipsilateral lower extremity requiring surgical repair
Permanent access site-related nerve injury (lasting&gt;30 days)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemostasis Success</measure>
    <time_frame>Within the first 10 minutes of cutting the MANTA suture</time_frame>
    <description>Hemostasis at the puncture site within 10 minutes of cutting the MANTA suture without need for manual or mechanical compression and without later re-bleeding (trivial or subcutaneous oozing will not be considered bleeding; light finger pressure to control subcutaneous oozing will not be considered manual compression)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Hemostasis</measure>
    <time_frame>Time between MANTA deployment and first observed and confirmed arterial hemostasis up to ten (10) minutes after MANTA device is deployed.</time_frame>
    <description>The elapsed time between MANTA deployment (withdrawal of sheath from artery) and first observed and confirmed arterial hemostasis (no or minimal subcutaneous oozing and the absence of expanding or developing hematoma).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Femoral Arteriotomy Closure</condition>
  <arm_group>
    <arm_group_label>MANTA Vascular Closure Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The MANTA device, developed by Essential Medical, Inc., is a vascular closure device (VCD) intended for use in catheterization laboratories following percutaneous cardiac or peripheral procedures that use the retrograde common femoral artery access route for large bore (10‐18F) interventional devices.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MANTA Vascular Closure Device</intervention_name>
    <description>The MANTA device developed by Essential Medical, Inc., is a vascular closure device (VCD) intended for use in catheterization laboratories following percutaneous cardiac or peripheral procedures that use the retrograde common femoral artery access route for large bore (10‐18F) interventional devices.</description>
    <arm_group_label>MANTA Vascular Closure Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Candidate for non-emergent transcatheter interventional procedure via a 10-18F femoral
             sheath (e.g., transcatheter aortic valve replacement [TAVR], balloon aortic
             valvuloplasty [BAV], Abdominal Aortic Aneurysm [AAA] stent-graft placement)

          -  Eligible for sheath removal in the catheterization lab

          -  Age ≥18 years

          -  Understand and sign the study specific written informed consent form

          -  Able and willing to fulfill the follow-up requirements

          -  In the Investigator's opinion, the patient is suitable for the MANTA vascular closure
             device, conventional hemostasis techniques and participation in an investigational
             trial

          -  Patients of childbearing age with Negative Pregnancy Test within 7 days of procedure

        Exclusion Criteria:

        Baseline Exclusions:

          -  Patients who are known to be pregnant or lactating

          -  Patients who are immunocompromised or with pre-existing autoimmune disease

          -  Patients who have a systemic infection or a local infection at or near the access site

          -  Patients requiring a re-puncture at a site previously punctured within 48 hours

          -  Patients with significant anemia (hemoglobin &lt; 6.5 mmol/l, Hct&lt;30)

          -  Patients who are morbidly obese or cachectic (BMI &gt;40 or &lt;20)

          -  Patients with Systolic Blood Pressure &gt;180 mmHg, unless Systolic Pressure can be
             lowered by pharmacological agents prior to closure

          -  Patients who are currently participating in another clinical trial of an
             investigational device or drug that has not concluded the follow-up period

          -  Patients in whom an antegrade puncture is performed or planned

          -  Patients with a known bleeding disorder including thrombocytopenia (platelet count
             &lt;150 x 10^9/L), thrombasthenia, hemophilia, or von Willebrand's disease

          -  Patients with a femoral artery &lt;6 mm in diameter, femoral artery stenosis resulting in
             a vessel diameter &lt;6 mm, or patients with severe peripheral vascular disease

          -  Common femoral artery with fluoroscopically visible calcium, as determined by Angio
             CT, precluding safe access in the opinion of the investigator

          -  Patients with allergy to bovine materials, collagen and/or collagen products, or
             polyglycolic or polylactic acid polymers

          -  Patients who cannot adhere to or complete the investigational protocol for any reason
             including but not limited to geographical residence or life threatening disease

          -  Patients with Sheehan Disability Scale (SDS) scores &gt;12

          -  Patients punctured through a vascular graft

          -  Patients with known allergy to stainless steel or nickel

          -  Patients who have acute ST-elevation myocardial infarction within 48 hours prior to
             procedure

          -  Patients with unilateral or bilateral lower extremity amputation

          -  Patients with renal insufficiency (serum creatinine &gt;2.5 mg/dl)

          -  Patients undergoing therapeutic thrombolysis

          -  Patients who are unable to ambulate at baseline

          -  Patients undergoing an interventional procedure whom are being treated with warfarin

          -  Patients requiring a continuous oral anticoagulation therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>San Raffaele Hospital</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Ben-Dor I, Looser P, Bernardo N, Maluenda G, Torguson R, Xue Z, Lindsay J, Pichard AD, Satler LF, Waksman R. Comparison of closure strategies after balloon aortic valvuloplasty: suture mediated versus collagen based versus manual. Catheter Cardiovasc Interv. 2011 Jul 1;78(1):119-24. doi: 10.1002/ccd.22940.</citation>
    <PMID>21681898</PMID>
  </reference>
  <reference>
    <citation>Nelson PR, Kracjer Z, Kansal N, Rao V, Bianchi C, Hashemi H, Jones P, Bacharach JM. A multicenter, randomized, controlled trial of totally percutaneous access versus open femoral exposure for endovascular aortic aneurysm repair (the PEVAR trial). J Vasc Surg. 2014 May;59(5):1181-93. doi: 10.1016/j.jvs.2013.10.101. Epub 2014 Jan 17.</citation>
    <PMID>24440678</PMID>
  </reference>
  <reference>
    <citation>Kadakia MB, Herrmann HC, Desai ND, Fox Z, Ogbara J, Anwaruddin S, Jagasia D, Bavaria JE, Szeto WY, Vallabhajosyula P, Li R, Menon R, Kobrin DM, Giri J. Factors associated with vascular complications in patients undergoing balloon-expandable transfemoral transcatheter aortic valve replacement via open versus percutaneous approaches. Circ Cardiovasc Interv. 2014 Aug;7(4):570-6. doi: 10.1161/CIRCINTERVENTIONS.113.001030. Epub 2014 Jul 15.</citation>
    <PMID>25027520</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>August 7, 2015</study_first_submitted>
  <study_first_submitted_qc>August 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2015</study_first_posted>
  <results_first_submitted>July 17, 2017</results_first_submitted>
  <results_first_submitted_qc>February 7, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 29, 2018</results_first_posted>
  <last_update_submitted>February 7, 2018</last_update_submitted>
  <last_update_submitted_qc>February 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MANTA</keyword>
  <keyword>Arterial Closure Device</keyword>
  <keyword>Large Bore Closure Device</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MANTA Vascular Closure Device (Total)</title>
          <description>The MANTA device, developed by Essential Medical, Inc., is a vascular closure device (VCD) intended for use in catheterization laboratories following percutaneous cardiac or peripheral procedures that use the retrograde common femoral artery access route for large bore (10‐18F) interventional devices.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not attend one or both follow-ups</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Total MANTA device population</population>
      <group_list>
        <group group_id="B1">
          <title>MANTA Vascular Closure Device (Total)</title>
          <description>The MANTA device, developed by Essential Medical, Inc., is a vascular closure device (VCD) intended for use in catheterization laboratories following percutaneous cardiac or peripheral procedures that use the retrograde common femoral artery access route for large bore (10‐18F) interventional devices.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79.5" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Major Complications</title>
        <description>Composite endpoint that includes any of the following adverse events:
Access site-related bleeding requiring blood transfusion or vascular repair
Vascular injury requiring repair (e.g. perforation, dissection, arterio-venous fistula, retroperitoneal bleed, pseudoaneurysm)
Femoral artery stenosis at the access site requiring intervention
New ipsilateral lower extremity ischemia causing a threat to the viability of the limb
Access site-related infection requiring intravenous antibiotics and/or extended hospitalization
New onset access site-related neuropathy in the ipsilateral lower extremity requiring surgical repair
Permanent access site-related nerve injury (lasting&gt;30 days)</description>
        <time_frame>Within either the first 30 days (plus or minus 7 days) after the procedure or the first 60 days (plus or minus 14 days) after the procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MANTA Vascular Closure Device (Total)</title>
            <description>The MANTA device, developed by Essential Medical, Inc., is a vascular closure device (VCD) intended for use in catheterization laboratories following percutaneous cardiac or peripheral procedures that use the retrograde common femoral artery access route for large bore (10‐18F) interventional devices.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Major Complications</title>
          <description>Composite endpoint that includes any of the following adverse events:
Access site-related bleeding requiring blood transfusion or vascular repair
Vascular injury requiring repair (e.g. perforation, dissection, arterio-venous fistula, retroperitoneal bleed, pseudoaneurysm)
Femoral artery stenosis at the access site requiring intervention
New ipsilateral lower extremity ischemia causing a threat to the viability of the limb
Access site-related infection requiring intravenous antibiotics and/or extended hospitalization
New onset access site-related neuropathy in the ipsilateral lower extremity requiring surgical repair
Permanent access site-related nerve injury (lasting&gt;30 days)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hemostasis Success</title>
        <description>Hemostasis at the puncture site within 10 minutes of cutting the MANTA suture without need for manual or mechanical compression and without later re-bleeding (trivial or subcutaneous oozing will not be considered bleeding; light finger pressure to control subcutaneous oozing will not be considered manual compression)</description>
        <time_frame>Within the first 10 minutes of cutting the MANTA suture</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MANTA Vascular Closure Device (Total)</title>
            <description>The MANTA device, developed by Essential Medical, Inc., is a vascular closure device (VCD) intended for use in catheterization laboratories following percutaneous cardiac or peripheral procedures that use the retrograde common femoral artery access route for large bore (10‐18F) interventional devices.</description>
          </group>
          <group group_id="O2">
            <title>14F MANTA Device</title>
            <description>14F subgroup of MANTA device</description>
          </group>
          <group group_id="O3">
            <title>18F MANTA Device</title>
            <description>18F subgroup of MANTA device</description>
          </group>
        </group_list>
        <measure>
          <title>Hemostasis Success</title>
          <description>Hemostasis at the puncture site within 10 minutes of cutting the MANTA suture without need for manual or mechanical compression and without later re-bleeding (trivial or subcutaneous oozing will not be considered bleeding; light finger pressure to control subcutaneous oozing will not be considered manual compression)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Hemostasis</title>
        <description>The elapsed time between MANTA deployment (withdrawal of sheath from artery) and first observed and confirmed arterial hemostasis (no or minimal subcutaneous oozing and the absence of expanding or developing hematoma).</description>
        <time_frame>Time between MANTA deployment and first observed and confirmed arterial hemostasis up to ten (10) minutes after MANTA device is deployed.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MANTA Vascular Closure Device (Total)</title>
            <description>The MANTA device, developed by Essential Medical, Inc., is a vascular closure device (VCD) intended for use in catheterization laboratories following percutaneous cardiac or peripheral procedures that use the retrograde common femoral artery access route for large bore (10‐18F) interventional devices.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Hemostasis</title>
          <description>The elapsed time between MANTA deployment (withdrawal of sheath from artery) and first observed and confirmed arterial hemostasis (no or minimal subcutaneous oozing and the absence of expanding or developing hematoma).</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.38" spread="6.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>60 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>MANTA Vascular Closure Device (Total)</title>
          <description>The MANTA device, developed by Essential Medical, Inc., is a vascular closure device (VCD) intended for use in catheterization laboratories following percutaneous cardiac or peripheral procedures that use the retrograde common femoral artery access route for large bore (10‐18F) interventional devices.</description>
        </group>
        <group group_id="E2">
          <title>Device Related Adverse Events</title>
          <description>Device related adverse events for the overall population</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <description>Not related to access site/MANTA device</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Minor Stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Excessive access site bleeding</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Bleeding/hemorrhage</sub_title>
                <description>Not related to access site or MANTA</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <description>All other AEs</description>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Excessive access site bleeding</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hematoma &gt;6cm</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hematoma &lt;= 6cm</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Femoral artery stenosis at access site</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Operations</name_or_title>
      <organization>Essential Medical, Inc</organization>
      <phone>610-557-1009</phone>
      <email>todd@essmedclosure.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

